ReShape Lifesciences Inc (RSLS)

Currency in USD
2.730
-0.620(-18.51%)
Closed·
Pre Market
2.575-0.155(-5.68%)
·
RSLS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual Pre-Market activity
Fair Value
Day's Range
2.6553.490
52 wk Range
2.230312.040
Key Statistics
Prev. Close
2.73
Open
3.38
Day's Range
2.655-3.49
52 wk Range
2.23-312.04
Volume
988.08K
Average Volume (3m)
2.66M
1-Year Change
-99.08%
Book Value / Share
9.3
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RSLS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

ReShape Lifesciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

ReShape Lifesciences Inc Company Profile

ReShape Lifesciences Inc. provides products and services that manage and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System to treat obesity and invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band to optimize an individual’s comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is involved in the development of the ReShape Obalon Balloon System, which consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and the Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in Irvine, California.

ReShape Lifesciences Inc Earnings Call Summary for Q4/2024

  • Revenue down 8% to $8M, gross profit fell 9% with 63.2% margin; operating costs cut 42% amid competitive pressures
  • Stock surged 65.58% in regular trading but fell 2.93% after hours; market cap at $1.88M with weak financial health score
  • Cash reserves at $700,000; company focused on cost management and expanding product portfolio through partnerships
  • Pending merger with Viome Therapeutics and asset sale to BI RADS; exclusive distribution agreement with Motion Informatics
  • CEO emphasizes disciplined resource management; CFO highlights 42% reduction in operating costs for 2024
Last Updated: 10/04/2025, 22:10
Read Full Transcript

Compare RSLS to Peers and Sector

Metrics to compare
RSLS
Peers
Sector
Relationship
P/E Ratio
−1.9x−4.4x−0.5x
PEG Ratio
-−0.270.00
Price/Book
5.3x2.9x2.6x
Price / LTM Sales
0.9x3.4x3.2x
Upside (Analyst Target)
-38.1%40.5%
Fair Value Upside
Unlock0.0%4.4%Unlock

Earnings

Latest Release
May 20, 2025
EPS / Forecast
18.98 / --
Revenue / Forecast
1.11M / --
EPS Revisions
Last 90 days

RSLS Income Statement

People Also Watch

1.27
KLTO
0.00%
2.24
BMGL
-2.18%
1.020
WINT
+4.83%
41.75
BMNR
+5.70%
3.17
RBNE
+0.96%

FAQ

What Stock Exchange Does ReShape Lifesciences Trade On?

ReShape Lifesciences is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for ReShape Lifesciences?

The stock symbol for ReShape Lifesciences is "RSLS."

What Is the ReShape Lifesciences Market Cap?

As of today, ReShape Lifesciences market cap is 6.51M.

What Is ReShape Lifesciences's Earnings Per Share (TTM)?

The ReShape Lifesciences EPS (TTM) is -96.22.

From a Technical Analysis Perspective, Is RSLS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has ReShape Lifesciences Stock Split?

ReShape Lifesciences has split 10 times.

How Many Employees Does ReShape Lifesciences Have?

ReShape Lifesciences has 18 employees.

What is the current trading status of ReShape Lifesciences (RSLS)?

As of 25 Jul 2025, ReShape Lifesciences (RSLS) is trading at a price of 2.73, with a previous close of 2.73. The stock has fluctuated within a day range of 2.66 to 3.49, while its 52-week range spans from 2.23 to 312.04.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.